Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Nu-Med Plus (NUMD) EBITDA (2016 - 2021)

Nu-Med Plus' EBITDA history spans 10 years, with the latest figure at -$109691.0 for Q4 2021.

  • Quarterly results put EBITDA at -$109691.0 for Q4 2021, up 78.19% from a year ago — trailing twelve months through Dec 2021 was -$830080.0 (up 58.52% YoY), and the annual figure for FY2025 was -$48955.0, up 22.7%.
  • EBITDA for Q4 2021 was -$109691.0 at Nu-Med Plus, up from -$115717.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $3.9 million in Q4 2017 to a low of -$905419.0 in Q2 2020.
  • The 5-year median for EBITDA is -$183789.0 (2018), against an average of -$71091.4.
  • The sharpest move saw EBITDA surged 314.28% in 2017, then crashed 286.46% in 2018.
  • Year by year, EBITDA stood at $3.9 million in 2017, then crashed by 109.02% to -$351627.0 in 2018, then skyrocketed by 42.36% to -$202668.0 in 2019, then plummeted by 148.11% to -$502832.0 in 2020, then skyrocketed by 78.19% to -$109691.0 in 2021.
  • According to Business Quant data, EBITDA over the past three periods came in at -$109691.0, -$115717.0, and -$250573.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.